Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 45

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 45
---
 but not limited to:

    ●
    the
    progress, timing, scope, and costs of our clinical trials, including the ability to timely enroll patients in our potential future
    clinical trials;

    ●
    the
    outcome, timing, and cost of regulatory approvals by the FDA and comparable regulatory authorities, including the potential that
    the FDA or comparable regulatory authorities may require that we perform more studies than those that we currently expect;

    ●
    the
    amount of revenues, if any, from our current clinical assets or any future clinical assets;

    ●
    the
    terms and timing of any potential future collaborations, licensing, or other arrangements that we may establish;

    ●
    cash
    requirements of any future acquisitions and/or the development of other clinical assets;

    ●
    the
    costs of operating as a public company;

    ●
    the
    time and cost necessary to respond to technological and market developments;

    ●
    any
    disputes which may occur between us, employees, collaborators, or other prospective business partners; and

    ●
    the
    costs of filing, prosecuting, defending, and enforcing any patent claims and other intellectual property rights

If
we raise additional funds by selling shares of our common stock or other equity-linked securities, the ownership interest of our current
stockholders will be diluted. We may seek to access the public or private capital markets whenever conditions are favorable, even if
we do not have an immediate need for additional capital at that time. If we raise additional funds through collaborations, strategic
alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our
technologies, future revenue streams, or clinical assets or to grant licenses on terms that may not be acceptable to us. If we raise
additional funds through debt financing, we may have to grant a security interest on our assets to the future lenders, our debt service
costs may be substantial, and the lenders may have a preferential position in connection with any future bankruptcy or liquidation involving
the Company.

55

On
March 27, 2025, the last quoted sale price for our common stock as reported on Nasdaq was $0.77 per share. Currently, the exercise
prices of the Company’s warrants are significantly greater than the current market price of our common stock. Accordingly,
such warrants are unlikely to be exercised and therefore the Company does not expect to receive any proceeds from such